TScan Therapeutics (TCRX) News Today $1.32 +0.11 (+9.09%) Closing price 04:00 PM EasternExtended Trading$1.36 +0.04 (+3.03%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TCRX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period TScan Therapeutics (NASDAQ:TCRX) Announces Quarterly Earnings ResultsTScan Therapeutics (NASDAQ:TCRX - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.28) by $0.02. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The business had revenue of $2.17 million for the quarter, compared to the consensus estimate of $1.62 million.May 14, 2025 | marketbeat.comEquities Analysts Set Expectations for TCRX Q2 EarningsTScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Research analysts at HC Wainwright increased their Q2 2025 EPS estimates for shares of TScan Therapeutics in a research report issued to clients and investors on Wednesday, May 7th. HC Wainwright analyst A. Fein now forecasts that the companyMay 13, 2025 | marketbeat.comHC Wainwright Issues Optimistic Outlook for TCRX EarningsMay 13, 2025 | americanbankingnews.comWedbush Equities Analysts Cut Earnings Estimates for TCRXTScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Research analysts at Wedbush lowered their Q2 2025 earnings estimates for TScan Therapeutics in a research report issued to clients and investors on Tuesday, May 6th. Wedbush analyst D. Nierengarten now anticipates that the company will postMay 11, 2025 | marketbeat.comHC Wainwright Expects Lower Earnings for TScan TherapeuticsMay 11, 2025 | americanbankingnews.comWedbush Reduces Earnings Estimates for TScan TherapeuticsMay 11, 2025 | americanbankingnews.comResearch Analysts Issue Forecasts for TCRX Q1 EarningsTScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Equities researchers at Wedbush issued their Q1 2026 earnings estimates for shares of TScan Therapeutics in a research note issued on Tuesday, May 6th. Wedbush analyst D. Nierengarten expects that the company will post earnings of ($0.23) perMay 10, 2025 | marketbeat.comWhat Analysts Are Saying About TScan Therapeutics StockMay 10, 2025 | nasdaq.comHC Wainwright Has Lowered Expectations for TScan Therapeutics (NASDAQ:TCRX) Stock PriceHC Wainwright cut their price target on TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday.May 9, 2025 | marketbeat.comTScan Therapeutics' (TCRX) "Outperform" Rating Reiterated at WedbushWedbush reissued an "outperform" rating and issued a $7.00 price target on shares of TScan Therapeutics in a research note on Tuesday.May 8, 2025 | marketbeat.com3TCRX : What Analysts Are Saying About TScan Therapeutics StockMay 7, 2025 | benzinga.comTScan Therapeutics (TCRX) to Release Earnings on MondayTScan Therapeutics (NASDAQ:TCRX) will be releasing its Q1 2025 earnings before the market opens on Monday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-12-tscan-therapeutics-inc-stock/)May 7, 2025 | marketbeat.comTScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 6, 2025 | globenewswire.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of "Buy" from AnalystsTScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) has earned an average recommendation of "Buy" from the six ratings firms that are currently covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 12 month price obMay 5, 2025 | marketbeat.comTScan Therapeutics Announces Abstract Acceptance for Poster Presentation at ASGCT 28th Annual MeetingApril 30, 2025 | nasdaq.comAdage Capital Partners GP L.L.C. Trims Position in TScan Therapeutics, Inc. (NASDAQ:TCRX)Adage Capital Partners GP L.L.C. reduced its position in TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) by 20.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 3,500,000 shares of the company's stock after selling 900,000 shares during the period. Adage CApril 30, 2025 | marketbeat.comTScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual MeetingApril 28, 2025 | globenewswire.comTScan Therapeutics (NASDAQ:TCRX) Earns Buy Rating from Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and issued a $9.00 price objective on shares of TScan Therapeutics in a research note on Tuesday.April 10, 2025 | marketbeat.comNeedham Sticks to Its Buy Rating for TScan Therapeutics (TCRX)April 9, 2025 | markets.businessinsider.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Given Consensus Rating of "Buy" by AnalystsShares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) have been assigned an average recommendation of "Buy" from the six brokerages that are currently covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating. The average twelve-month price objApril 9, 2025 | marketbeat.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Short Interest UpdateTScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) was the recipient of a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 1,900,000 shares, a decrease of 14.8% from the February 28th total of 2,230,000 shares. Based on an average trading volume of 433,800 shares, the days-to-cover ratio is currently 4.4 days. Approximately 4.4% of the shares of the stock are short sold.April 2, 2025 | marketbeat.comTScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | globenewswire.comTScan Therapeutics appoints Camiolo as SVP, Market AccessMarch 27, 2025 | markets.businessinsider.comTScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market AccessMarch 27, 2025 | globenewswire.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Recommendation of "Buy" by BrokeragesTScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) has received a consensus rating of "Buy" from the six research firms that are currently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a buy rating. The average 1 year target price among analysts thaMarch 15, 2025 | marketbeat.comTScan Therapeutics' (TCRX) "Overweight" Rating Reiterated at Morgan StanleyMorgan Stanley restated an "overweight" rating and set a $10.00 price target on shares of TScan Therapeutics in a report on Friday.March 15, 2025 | marketbeat.comTScan Therapeutics assumed with an Overweight at Morgan StanleyMarch 14, 2025 | markets.businessinsider.comTScan Therapeutics’ SWOT analysis: biotech stock navigates clinical milestonesMarch 14, 2025 | uk.investing.comQ2 EPS Estimate for TScan Therapeutics Lowered by AnalystTScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Investment analysts at HC Wainwright dropped their Q2 2025 earnings per share (EPS) estimates for shares of TScan Therapeutics in a report released on Thursday, March 6th. HC Wainwright analyst A. Fein now anticipates that the company will poMarch 10, 2025 | marketbeat.comBarclays Has Lowered Expectations for TScan Therapeutics (NASDAQ:TCRX) Stock PriceBarclays reduced their target price on TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating on the stock in a report on Friday.March 8, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for TCRX FY2029 Earnings?TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Equities researchers at HC Wainwright issued their FY2029 EPS estimates for shares of TScan Therapeutics in a research note issued on Thursday, March 6th. HC Wainwright analyst A. Fein forecasts that the company will post earnings of $0.44 peMarch 8, 2025 | marketbeat.comTScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025March 7, 2025 | seekingalpha.comTScan Therapeutics price target lowered to $3 from $14 at BarclaysMarch 7, 2025 | markets.businessinsider.comTScan Therapeutics (NASDAQ:TCRX) Receives "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $15.00 target price on shares of TScan Therapeutics in a research report on Thursday.March 7, 2025 | marketbeat.comWedbush Reiterates "Outperform" Rating for TScan Therapeutics (NASDAQ:TCRX)Wedbush restated an "outperform" rating and set a $7.00 price target on shares of TScan Therapeutics in a report on Wednesday.March 6, 2025 | marketbeat.comNeedham & Company LLC Cuts TScan Therapeutics (NASDAQ:TCRX) Price Target to $9.00Needham & Company LLC decreased their price objective on shares of TScan Therapeutics from $11.00 to $9.00 and set a "buy" rating for the company in a report on Wednesday.March 6, 2025 | marketbeat.comTScan Therapeutics (NASDAQ:TCRX) Issues Quarterly Earnings ResultsTScan Therapeutics (NASDAQ:TCRX - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.02). TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%.March 6, 2025 | marketbeat.comTScan Therapeutics reports Q4 EPS (30c), consensus (28c)March 6, 2025 | markets.businessinsider.comTScan Therapeutics files $300M mixed securities shelfMarch 6, 2025 | markets.businessinsider.comTScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 5, 2025 | globenewswire.comTScan Therapeutics (NASDAQ:TCRX) Stock Price Down 11.9% - Here's What HappenedTScan Therapeutics (NASDAQ:TCRX) Trading Down 11.9% - Here's WhyMarch 4, 2025 | marketbeat.comTScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care ConferenceFebruary 27, 2025 | globenewswire.comTScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual ConferenceFebruary 18, 2025 | globenewswire.comTScan Therapeutics: Finding Their Footing After An Eventful ASH MeetingFebruary 10, 2025 | seekingalpha.comabrdn plc Has $2.69 Million Stake in TScan Therapeutics, Inc. (NASDAQ:TCRX)abrdn plc increased its position in TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) by 137.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 883,704 shares of the company's stock after buying an additional 512,049 shares during the period.February 10, 2025 | marketbeat.comTScan Therapeutics Insider Ups Holding By 18% During YearFebruary 5, 2025 | finance.yahoo.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Short Interest Down 20.6% in JanuaryTScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) was the recipient of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 2,000,000 shares, a decrease of 20.6% from the December 31st total of 2,520,000 shares. Approximately 4.6% of the company's shares are sold short. Based on an average daily volume of 403,800 shares, the days-to-cover ratio is currently 5.0 days.February 1, 2025 | marketbeat.comBarclays Sticks to Its Buy Rating for TScan Therapeutics (TCRX)January 16, 2025 | markets.businessinsider.comTScan Therapeutics' SWOT analysis: innovative t-cell therapy stock faces pivotal yearJanuary 16, 2025 | msn.comTScan Shares Jump 23% on Securities Purchase AgreementDecember 26, 2024 | marketwatch.com Get TScan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address TCRX Media Mentions By Week TCRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TCRX News Sentiment▼1.040.65▲Average Medical News Sentiment TCRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TCRX Articles This Week▼22▲TCRX Articles Average Week Get TScan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Fulcrum Therapeutics News Today Atyr PHARMA News Today Atai Life Sciences News Today Aurora Cannabis News Today Aquestive Therapeutics News Today Compass Therapeutics News Today DBV Technologies News Today Corvus Pharmaceuticals News Today Cartesian Therapeutics News Today Immutep News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TCRX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TScan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TCRX Stock Free TCRX Stock Alerts